This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
.sub-header{display:none;}
Lev Gerlovin, Ezra Josephson | Life Sciences
–>
Lev Gerlovin explores the future of payer response to rising drug prices and discuss strategies that manufacturers may consider to gain a competitive edge in this evolving landscape.
This report identifies two key policy objectives that can be generated from healthcare and pharmaceutical spending.
Key takeaways Men with prostate cancer are more likely to die from heart disease, not cancer. Patients who start androgen deprivation therapy (ADT) are...
CRA is a proud sponsor of the summit. Simon Chisholm is a speaker during the session titled “Understanding Lessons and Takeaways from Market Investigations”...
CRA is a proud sponsor of the conference dedicated to providing invaluable opportunities for networking and collaboration with the chance to meet, engage with...
